GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Product-specific reference

Apixaban - adult oral tablets

Read renal action and limits
Local official-label summarySource retrieved 2026-09-05See the evidence for this drug5 sources available - open source summaries, references and comparisons

Eliquis / Apixaban

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (5)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Eliquis - product and source limitations

The AF criteria do not determine the adult VTE regimen. Dialysis patients were excluded from efficacy trials and dialysis recommendations rely on exposure data.

Before applying: Apply only to the stated formulation, indication and renal population.

Also check: Eliquis - product and source limitations

Professional source

AAFP - correction separating AF and VTE dose rules

Choose a product and source Eliquis | Product label Eliquis | GlobalRPh RX passage All evidence
Product / population
Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal measure
Indication-specific age/weight/serum-creatinine criteria; do not substitute a universal CrCl cutoff
Source revision
2018; historical letter and author correction
Retrieved
2026-09-05 (not the revision date)

Dosing / renal protocol and limits

This historical published correction warns against applying atrial-fibrillation dose-reduction criteria to VTE treatment. The 2.5 mg twice-daily AF reduction requires at least two of: age >=80 years, weight <=60 kg, serum creatinine >=1.5 mg/dL, not one criterion. The reply explains that the manufacturer did not recommend the same reduction for VTE.

The authors emphasize limited trial data in advanced kidney disease: AMPLIFY excluded very low clearance, while dialysis recommendations relied on pharmacokinetic/pharmacodynamic information. This 2018 correction supports indication separation, not a new dialysis efficacy claim or a replacement for current labeling.

Source revision: 2018; historical letter and author correction | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://www.aafp.org/afp/2018/0415/p496

Scope: Locally included source-specific summary. Regimen differences are not automatically resolved. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Added / rechecked in v7.4

Read source findings

Read source-specific summaries and their qualifications. Retrieval date is not label revision date. Recent review does not imply clinical approval.

Official

Eliquis - labeled renal guidance

Retrieved: 2026-11-07
Source revision: DailyMed SPL version 5, posted Sep 25, 2026

Renal measure: Serum creatinine (mg/dL), age (years) and weight (kg)

Read this dated source finding
Rxlist

Eliquis - selected RX renal passage

Retrieved: 2026-11-07
Source revision: Mirror revision not established in the reviewed passage.

Renal measure: Use the renal measure explicitly present in the RX passage.

Read this dated source finding
See all retained evidence sources
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Eliquis - labeled renal guidance

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Apixaban (Eliquis), adult oral tablets, nonvalvular AF

Renal method: Serum creatinine (mg/dL), age (years) and weight (kg)
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
GlobalRPh RX List

Eliquis - selected RX renal passage

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Apixaban (Eliquis), adult oral tablets, nonvalvular AF

Renal method: Use the renal measure explicitly present in the RX passage.
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
Professional guidance

AAFP - correction separating AF and VTE dose rules

Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: Indication-specific age/weight/serum-creatinine criteria; do not substitute a universal CrCl cutoff
Retrieved: 2026-09-05

Read local renal resultOpen this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Eliquis - product and source limitations

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

Eliquis - product and source limitations

The AF criteria do not determine the adult VTE regimen. Dialysis patients were excluded from efficacy trials and dialysis recommendations rely on exposure data.

How to use this: Apply only to the stated formulation, indication and renal population.

Eliquis - labeled renal guidanceEliquis - selected RX renal passage

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Professional source

AAFP - correction separating AF and VTE dose rules

Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Method: Indication-specific age/weight/serum-creatinine criteria; do not substitute a universal CrCl cutoff

Dosing / renal protocol and limitsRead this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeELIQUIS (apixaban) tabletsEliquis - labeled renal guidanceEliquis - selected RX renal passageAAFP - correction separating AF and VTE dose rulesRenal Drug Handbook, fifth edition
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

The handbook's GFR-based 2.5 mg twice-daily AF rows differ from the U.S. label's combined age, weight and serum-creatinine criteria. Dialysis evidence is limited. No combined algorithm has been generated.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0

Product and population scope

ELIQUIS oral tablets for adults. Atrial-fibrillation and venous-thromboembolism regimens must remain separate. Pediatric tablets/suspension and pediatric renal rules are outside this page's scope.

apixaban-adult:scope · Source section: Selected U.S. label: product title, route, dosage form and indicationRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

ELIQUIS (apixaban) tablets

Open original reference

Open / share this exact local source

NIH/NLM DailyMed - U.S. prescribing information · Adults; oral tablets.

Renal method: Not specified in this summary.
Source date:
Retrieved: 2026-09-05

Source-read local summary; source-specific recommendations are not automatically interchangeable.

Adult indication-specific doses

Nonvalvular AF: 5 mg twice daily; use 2.5 mg twice daily when at least two apply: age >=80 years, weight <=60 kg, serum creatinine >=1.5 mg/dL. Acute DVT/PE: 10 mg twice daily for 7 days, then 5 mg twice daily. Recurrence reduction: 2.5 mg twice daily after at least 6 months of treatment.

apixaban-adult:dm-e9481622-7cc6-418a-acb6-c5450daae9b0-1 · Source locator: 2.1

Renal evidence limits

Do not apply the AF reduction criteria to VTE treatment. For adult VTE indications, the label specifies no renal dose change, including dialysis, but CrCl <15 and dialysis patients were not enrolled in efficacy/safety studies; recommendations rely on pharmacokinetic/pharmacodynamic data. AF dialysis exposure is described, but comparable stroke and bleeding outcomes remain unknown.

apixaban-adult:dm-e9481622-7cc6-418a-acb6-c5450daae9b0-2 · Source locator: 8.6

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0
Retrieved
2026-09-05
Exact label title
ELIQUIS (apixaban) tablets
DailyMed Set ID
e9481622-7cc6-418a-acb6-c5450daae9b0
Labeler
E.R. Squibb & Sons, L.L.C.
DailyMed page updated
2025-04-17
FDA application
NDA marketing category
U.S. product identity basis
Exact named product and route appear in the selected U.S. prescription label; current retail availability was not independently assessed.
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
9b15132c7d33d09a8c930e78d99a0882528575621939922e38ab33cccacd8e0b
Official

Eliquis - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Apixaban (Eliquis), adult oral tablets, nonvalvular AF

Renal method: Serum creatinine (mg/dL), age (years) and weight (kg)
Source date: DailyMed SPL version 5, posted Sep 25, 2026
Retrieved: 2026-11-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 2.1 and 8.6

For adult nonvalvular AF, use 2.5 mg twice daily when at least two are present: age 80 years or older, body weight 60 kg or less, or serum creatinine at least 1.5 mg/dL. The AF criteria do not determine the adult VTE regimen. Dialysis patients were excluded from efficacy trials and dialysis recommendations rely on exposure data.

RDM74-eliquis-official-1 · Source locator: Renal guidance: 2.1 and 8.6

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=41a133ef-e461-48ad-8221-b735bdd0ec25
Retrieved
2026-11-07
Renal-function method
Serum creatinine (mg/dL), age (years) and weight (kg)
Source date/version
DailyMed SPL version 5, posted Sep 25, 2026
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
a9a94819b0a0292799820deb133794c382a14a15f589276aef9c0f9812994695
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Eliquis - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Apixaban (Eliquis), adult oral tablets, nonvalvular AF

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

The adult dialysis discussion describes pharmacokinetic support and the absence of dialysis patients from the efficacy trials.

RDM74-eliquis-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/eliquis-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
8458acd218ce0cb3c4f9d462945da0d6695301b2fe98f8d5684d54027888a1f9
Separate handbook layer

Renal Drug Handbook cross-check

Handbook

Renal Drug Handbook, fifth edition

Open / share this exact local source

UK Renal Pharmacy Group / Ashley and Dunleavy / CRC Press · Historical 2019 reference; renal bands retain the book's own method labels.

Renal method: Not specified in this summary.
Source date: Not established
Retrieved: 2026-09-05

Historical handbook facts locally summarized; not a current U.S. label or a modern CRRT protocol.

Historical renal bands

The book lists usual dosing with caution at GFR 30-50 mL/min. At 15-30 it retains usual dosing for non-AF indications but lists 2.5 mg twice daily for AF. Below 15 it lists cautious use and 2.5 mg twice daily for AF. These are historical UK-reference statements, not the U.S. label's AF dose-reduction algorithm.

apixaban-adult:rdh5-73-74-1 · Source locator: Printed page 73: Dose in renal impairment

Historical renal-replacement information

APD/CAPD: unlikely to be removed; refer to the <15 band. HD: described as not dialysed, with the same band. HDF/high-flux removal is unknown and uses the <15 band; CAV/VVHD removal is unknown and uses 15-30. The next page reports HD reducing exposure by 14%, so "not dialysed" must not be read as literally zero removal.

apixaban-adult:rdh5-73-74-2 · Source locator: Printed pages 73-74: renal replacement; Other information

Source-specific limits

The book also reports lack of manufacturer recommendation in severe impairment. This historical discussion is not evidence for routine current initiation on dialysis. Use the separately stated U.S. indication-specific criteria, and assess the evidence limitations.

Source identity and provenance
Retrieved
2026-09-05
Handbook page
Printed page 73-74; PDF page 92-93
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
4fc3f322f6c20a949eb0b138e44e46f6492473c813e3705f99b929a085a4e3c0
Separate professional-source layer

University and professional protocols

Professional

AAFP - correction separating AF and VTE dose rules

Open original reference

Open / share this exact local source

American Academy of Family Physicians / American Family Physician · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: Indication-specific age/weight/serum-creatinine criteria; do not substitute a universal CrCl cutoff
Source date: 2018; historical letter and author correction
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

This historical published correction warns against applying atrial-fibrillation dose-reduction criteria to VTE treatment. The 2.5 mg twice-daily AF reduction requires at least two of: age >=80 years, weight <=60 kg, serum creatinine >=1.5 mg/dL, not one criterion. The reply explains that the manufacturer did not recommend the same reduction for VTE.

The authors emphasize limited trial data in advanced kidney disease: AMPLIFY excluded very low clearance, while dialysis recommendations relied on pharmacokinetic/pharmacodynamic information. This 2018 correction supports indication separation, not a new dialysis efficacy claim or a replacement for current labeling.

RDM30-102-apixaban-adult-1 · Source locator: AAFP - correction separating AF and VTE dose rules; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://www.aafp.org/afp/2018/0415/p496
Retrieved
2026-09-05
Renal-function method
Indication-specific age/weight/serum-creatinine criteria; do not substitute a universal CrCl cutoff
Source date/version
2018; historical letter and author correction
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
fdc1136e4610fcacccb66a391b5df3a922256d41fe00a284f277cf387c19e84f

Provenance and preservation

Additional summaries stored on this page: 2 official-label, 1 RX List, 1 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
handbook us addition
Local text SHA-256
e5e26c127fd42936c58823ce049ff013a9859809ac9b2e7023474f9a8abb3e06
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report
Top